Oncology Flashcards

1
Q

Indication for masectomy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Indication for chest wall radiation after masectomy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indication for adjuvant therapy for breast cancer

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Should new breast cancer mets be biopsied?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Small Cell Lung Cancer characteristics

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gastric Cancer Treatment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hereditary nonpolyposis colon cancer diagnostic criteria

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Colon cancer treatment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Follow-up for colon cancer

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

treatment of anal cancer

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HCC treatment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment of Neuroendocrine tumors

A
18
Q

Ovarian Cancer Testing

A
19
Q

Ovarian Cancer Treatment

A
20
Q

Treatment of endometrial cancers

A
21
Q

Treatment of Prostate Cancer

A
22
Q

Testicular Cancer Testing

A
23
Q

Testicular Cancer Treatment

A
24
Q

RCC related disease

A
25
Q

Treatment of RCC

A
26
Q

Types of Thyroid Cancer

A
27
Q

Treatment of thyroid cancer

A
28
Q

Indolent Lymphoma

A
29
Q

Agrressive Lymphoma

A
30
Q

Hodgkins Lymphoma Treatment

A
31
Q
A
32
Q
A
33
Q

Treatment of Neutropenic Fevers

A
34
Q
A
35
Q
A
36
Q

High-risk prostate cancer

A

prostate-specific antigen (PSA) level greater than 20 ng/mL (20 µg/L), a Gleason score of 8 to 10, or evidence of extraprostatic extension of the cancer.

37
Q

advanced-stage follicular lymphoma treatment

A

rituximab plus chemotherapy leads to remission in more than 90% of patients, although the disease will recur in most patients.

38
Q

aggressive B-cell lymphomas types

A

diffuse large B-cell and Burkitt lymphoma

39
Q

aggressive B-cell lymphomas treatment

A

Standard therapy for most patients with advanced-stage diffuse large B-cell lymphoma is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

40
Q

Hodgkin lymphoma diagnosis

A

established with a lymph node biopsy specimen showing Reed-Sternberg cells

41
Q

Hodgkin lymphoma treatment

A

All patients with classic Hodgkin lymphoma, regardless of stage, receive chemotherapy(doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)).

Patients with early-stage nodular lymphocyte–predominant Hodgkin lymphoma may be treated with radiation alone, but in the more advanced stages, they should be treated with rituximab with or without chemotherapy.

Complete response indicated by PET scan after two to three cycles of chemotherapy can allow some patients with early-stage classical Hodgkin lymphoma to forgo radiation therapy.

42
Q

Toxicities:

Fluoropyrimidines (5-fluorouracil and capecitabine)

Epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib):

Monoclonal antibodies against EGFR (cetuximab and panitumumab):

Trastuzumab:

Bleomycin:

Gemcitabine:

Cisplatin:

Bevacizumab:

A

Toxicities:

Fluoropyrimidines (5-fluorouracil and capecitabine): palmar-plantar erythrodysesthesia (“hand-foot syndrome”), coronary vasospasm, cerebellar toxicity

Epidermal growth factor receptor (EGFR) inhibitors (erlotinib and gefitinib): pustular acneiform eruptions, pulmonary toxicity

Monoclonal antibodies against EGFR (cetuximab and panitumumab): pustular acneiform eruptions, pulmonary toxicity

Trastuzumab: pulmonary toxicity

Bleomycin: pulmonary toxicity

Gemcitabine: Hemolytic uremic syndrome

Cisplatin: acute tubular necrosis, Peripheral neuropathy

Bevacizumab: hypertension, reversible posterior encephalopathy syndrome

pembrolizumab and nivolumab (anti–programmed death receptor-1 [PD-1]): colitis, pneumonitis, hepatitis, dermatitis, hypophysitis, thyroiditis, and adrenalitis.